TNF and chronic recurrent multifocal osteomyelitis: Regarding the former case, the patient was under therapy with the TNF inhibitor etanercept, which was not discontinued due to the good clinical course of CRMO, and the cutaneous and contiguous bony lesions improved with a cycle of steroids; it was the only case in the series in which anti TNF agents were employed for the CRMO (Table 1).